Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-05-09
2006-05-09
Chang, Celia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07041680
ABSTRACT:
Substituted 2-(2,6-dioxopiperidin-3-yl) phthalimides and 1-oxo-2-(2,6-dioxopiperidin-3-yl) isoindolines reduce the levels of TNFα in a mammal. Typical embodiments are 1-oxo-2-(2,6-dioxo-3-methylpiperidin-3-yl)-4,5,6,7-tetrafluoroisoindoline and 1,3-dioxo-2-(2,6-dioxo-3-methylpiperidin-3-yl)-4-aminoisoindoline.
REFERENCES:
patent: 5593990 (1997-01-01), D'Amato
patent: 5629327 (1997-05-01), D'Amato
patent: 5635517 (1997-06-01), Muller et al.
patent: 5712291 (1998-01-01), D'Amato
patent: 5874448 (1999-02-01), Muller et al.
patent: 5955476 (1999-09-01), Muller et al.
patent: 6071948 (2000-06-01), D'Amato
patent: 6114355 (2000-09-01), D'Amato
patent: 6228879 (2001-05-01), Green et al.
patent: 6235756 (2001-05-01), D'Amato
patent: 6281230 (2001-08-01), Muller et al.
patent: 6316471 (2001-11-01), Muller et al.
patent: 6335349 (2002-01-01), Muller et al.
patent: 6403613 (2002-06-01), Man et al.
patent: 6420414 (2002-07-01), D'Amato
patent: 6458810 (2002-10-01), Muller et al.
patent: 6469045 (2002-10-01), D'Amato
patent: 6476052 (2002-11-01), Muller et al.
patent: 6518298 (2003-02-01), Green et al.
patent: 6555554 (2003-04-01), Muller et al.
patent: WO 94/20085 (1994-09-01), None
patent: WO 98/19649 (1998-05-01), None
patent: WO 02/064083 (2002-08-01), None
patent: WO 02/070480 (2002-09-01), None
Niahimura et al. “S-form of methyln-phthalimidoglutaimide . . . ” CA121:73088 (1994).
D'Amato et al. “S-3-aminophathalimido-glutarimide . . . ” Cancer res. 62(8)2300-2305 (2002).
Al-Soud et al., “Synthesis and antitumor activity of some phthalimide analogues”, Pharmazie 56(5): 372-275 (2001).
Bauer et al., “Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent”, Biochem Pharmacol 55(11): 1827-1834 (1998).
Boylen et al., “Teratogenic Effects of Thalidomide and Its Metabolites on the Developing Chick Embryo,” Canadian J. of Biochem., 42 (1964).
Buelens, “Treatment of a grade II astrocytoma with thalidomide”, Arzneimittel-Forschung 17: 646-648 (1967).
Colville-Nash et al., “Angiogenesis and Rheumatoid Arthritis: Pathogenic and Therapeutic Implications,” Ann. Rheum. Dis., 51(7): 919-25 (1992).
Craig et al., “Potential anticancer agents. III. 2-phthalimidoaldehydes and derivatives”, Potential Anticancer Agents. III 10: 1 071-1073 (1967).
D'Amato et al., “Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma”, Semin. Oncol. 28:597-601 (2001).
D'Amato et al., “Thalidomide is an Inhibitor of Angiogenesis”, Proc. Natl. Acad. Sci. 91:4082-4085 (1994).
De et al., “Hansch analysis for some antineoplastic glutarimides”, J. Indian Chem. Soc. I.III: 825-826 (1976).
De et al., “Possible antineoplastic agents I”, Jour. Pharm. Sci. 64(2): 262-266 (1975).
De et al., “Possible antineoplastic agents II”, J. Pharmaceutical Sciences 66(2): 232-235 (1977).
De et al., “Possible antineoplastic agents: III. Synthesis of 6-alkyl-2-[4′-methoxyphthalimido] 6-alkyl-3-[3′-4′-dimethoxyphenyl] glutarimides”, J. Indian Chem. Soc. I.III: 1122-1125 (1976).
De et al., “Possible antineoplastic agents: part IV—synthesis & antineoplastic potency of N-substituted a-(4,5-dimethoxyphthalimido)glutarimides & B-(4-bromophenyl)glutarimides”, Indian Jour. Chem. 16B: 510-512 (1978).
De et al., “Quantitative structure-activity relationship (QSAR) and rational drug design for some antineoplastic thalidomide and glutarimide derivatives”, J. Indian Chem. Soc. LIII: 1049-1052 (1976).
DiPaolo, “In vitro test systems for cancer chemotherapy,II, correlation of in vitro inhibition of dehydrogenase and growth with in vivo inhibition of Ehrlich ascites tumor”, P.S.E.B.M. 114: 384-387 (1963).
Fabro et al., “Teratogenic Activity of Thalidomide and Related Compounds,” Life Sciences, 3: 987-92 (1964).
Folkman et al., “Angiogenesis,” J. Biol. Chem., 267(16): 10931-4 (1992).
Gelato et al., “Inhibition of prolactin release by a thalidomide-related compound”, P.S.E.B.M. 114: 167-168 (1972).
Gershbein, “The thalidomide analog, EM 12, enhances 1,2-dimethylhydrazine-induction of rat colon adenocarcinomas”, Cancer Letters 60: 129-133 (1991).
Grabstald et al., “Clinical experiences with thalidomide in patients with cancer”, Clinical Pharmacology and Therapeutics 6: 298-302 (1965).
Jonsson, “Chemical Structure and Teratogenic Properties,” Acta Pharma. Succica, 9: 521-542 (1972).
Koch, “The Arene Oxide Hypothesis of Thalidomide Action: Consideration s on the Molecular Mechanism of Action of the ‘Classical’ Teratogen,” Sci. Pharm., 49: 67-99 (1981).
Koch, “Thalidomide and Cogeners as Anti-inflammatory Agents,” Medicinal Chemistry, 22 (1985).
Lentzsch et al., “S-3-amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice”, Cancer Research 62:2300-2305 (2002).
Luzzio et al., “Synthesis and antiangiogenic activity of 2-deoxygenated analogs in 6′-deoxygenated metabolic analogs of thalidomide”, MEDI, Abstract No. 185.
Menard et al., “Quelques Metabolites Possibles de la Thalidomide,” Canadian J. Chem., 41: 1722-5 (1963).
Miyachi et al., “Novel biological response modifiers: phthalimides with tumor necrosis factor-alpha production-regulating activity”, J. Med. Chem. 40: 2858-2865 (1997).
Muckter, “Thalidomide and tumer”, Antimicrobial Agents and Chemotherapy, 531-538 (1965).
Olson et al., “Thalidomide (N-phthaloylglutamimide) in the treatment of advanced cancer”, Clinical Pharmacology and Therapeutics 6(3): 292-297 (1965).
Schumacher et al., “The Metabolism of Thalidomide: The Fate of Thalidomide and Some of its Hydrolysis Products in Various Species,” Brit. J. Pharmacol., 25: 338-351 (1965).
Schweigerer et al., “Angiogenesis and Angiogenesis Inhibitors in Pediatric Diseases,” Eur. J. Pediatrics, 151: 472-476 (1992).
Shah et al., “Synthesis and enantiomeric separation of 2-phthalimidino-glutaric acid analogues: potent inhibitors of tumor metastasis”, J. Med. Chem. 42:3014-3017 (1999).
Shibata et al., “N-alkylphthalimides: structural requirment of thalidomidal action on 12-0-tetradecanoylphorbol-13-acetate-induced tumor necrosis factor a production by human leukemia HL-60 cells”, Chem. Pharm. Bull. 43(1): 177-179 (1995).
Shimazawa et al., “Antiangiogenic activity of tumor necrosis factor-alpha production regulators derived from thalidomide”, Biol. Pharm. Bull. 22(2): 224-226 (1999).
Smith et al., “Studies on the Relationship Between the Chemical Structure and Embyotoxic Activity of Thalidomide and Related Compounds,” A Symposium on Embryopathic Activity of Drugs, London (1965).
Suaer et al., “Thalidomide inhibits angiogenesis in embryoid bodies by the generation of hydroxyl radicals”, Am. J. Pathol. 156(1): 151-158 (2000).
Sugiura et al., “Effects of thalidomide on transplantable mouse, rat, and hamster tumors”, GANN 55: 57-60 (1964).
Torry et al., “Angiogenesis in the Uterus: Potential Regulation and Relation to Tumor Angiogenesis,” Am. J. Reproductive Immunol., 27: 171-9 (1992).
Traldi et al., “L'impiego dell'imide dell'acido N-ftalilglutammico (talidomide) nella terapia sintomatica del vomito di molti pazienti affetti da neoplasie maligne o causato della somministrazione di cloridato di mecloretamina”, Cancro 18:336-341 (1965).
Udagawa et al., “Thalidomides and analogs”, Antiangiogenic Agents in Cancer Therapy, Humana Press, Totowa, NJ, pp. 263-274 (1998).
He et al., 1993, “Synthesis of thalidomide analogs and their biological potential for treatment of graft versus host disease,” a full article ofJ. Am. Chem. Soc.
Chen Roger Shen-Chu
Muller George W.
Stirling David I.
Celgene Corporation
Chang Celia
Day Jones
LandOfFree
(R) and (S) isomers of substituted... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with (R) and (S) isomers of substituted..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and (R) and (S) isomers of substituted... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3601693